Lucentis

Lucentis

ranibizumab

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ranibizumab
Indications/Uses
Adults w/ neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (branch or central RVO), choroidal neovascularization (CNV), & CNV secondary to pathologic myopia (PM); moderately severe to severe non-proliferative diabetic retinopathy (NPDR) & proliferative diabetic retinopathy (PDR). Preterm infants w/ retinopathy of prematurity (ROP).
Dosage/Direction for Use
Intravitreal Adult 0.5 mg as single inj. Interval between 2 doses inj into the same eye should not be <1 mth. Wet AMD, DME, moderately severe to severe NPDR or PDR, macular edema secondary to RVO, CNV, CNV secondary to PM Initially 1 inj/mth until max visual acuity is achieved &/or there are no signs of disease activity. May be extended by 2 wk at time for wet AMD & central RVO or by 1 mth at time for DME & branch RVO when treated w/ treat-&-extend regimen. Visual impairment due to CNV secondary to PM 1 or 2 inj during the 1st yr. Some patients may need more frequent treatment. Laser photocoagulation in DME & branch RVO When given on the same day, administer at least 30 min after laser photocoagulation. Pre-term infant ROP Initially 0.2 mg as single inj. May be given bilaterally on the same day.
Contraindications
Hypersensitivity. Patients w/ active or suspected ocular or periocular infections; active intraocular inflammation.
Special Precautions
Endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear & iatrogenic traumatic cataract. Transient increases in IOP w/in 60 min of inj & sustained IOP increases. Potential risk of arterial thromboembolic events; immunogenicity. Bilateral treatment. Patients w/ known risk factors for stroke including history of prior stroke or transient ischemic attack; active systemic infections or concurrent eye conditions eg, retinal detachment or macular hole. Monitor patients during the wk following inj; IOP & optic nerve head perfusion. May affect ability to drive or use machines. Females of reproductive potential should use effective contraception during treatment. Not to be used during pregnancy (wait at least 3 mth after last dose before becoming pregnant). Not recommended during lactation. Not recommended in childn & adolescents.
Adverse Reactions
Nasopharyngitis; headache; intraocular inflammation, vitritis, vitreous detachment, retinal & conjunctival haemorrhage, visual disturbance, eye pain, irritation or pruritus, vitreous floaters, foreign body sensation in eyes, increased lacrimation, blepharitis, dry eye, ocular hyperemia; arthralgia; increased IOP. Flu, UTI (DME population only); anemia; anxiety; stroke; retinal degeneration, disorder, detachment or tear, retinal pigment epithelium detachment & tear, reduced visual acuity, vitreous haemorrhage & disorder, uveitis, iritis, iridocyclitis, cataract, subcapsular cataract, posterior cap opacification, punctate keratitis, corneal abrasion, anterior chamber flare, blurred vision, inj site haemorrhage, eye hemorrhage & discharge, conjunctivitis, allergic conjunctivitis, photopsia, photophobia, ocular discomfort, eyelid oedema & pain, conjunctival hyperemia; cough; nausea; allergic reactions eg, rash, urticaria, pruritus, erythema.
MIMS Class
Other Eye Preparations
ATC Classification
S01LA04 - ranibizumab ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.
Presentation/Packing
Form
Lucentis soln for inj 10 mg/mL
Packing/Price
0.23 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in